Roche Phase III Success Rate Tops 70%, Double That Of Late '90s
This article was originally published in The Pink Sheet Daily
Executive Summary
The increase in rate of Phase III projects moving to registration stage over the last four years is largely due to positive outcomes from studies completed in 2004. Out of 12 major Phase III clinical trials completed over the last year, only pemtumomab in ovarian cancer did not meet its primary endpoint.